Selenium Intervention Pilot and Feasibility Study in Heart Failure (SIP-HF)

The SIP-HF aims to prepare for a large-scale trial on selenium supplementation´s efficacy in heart failure (HF) patients.

Objectives include finalizing the study design, securing approvals, coordinating centers, and conducting a pilot study with 100 patients per arm across five hospitals to identify recruitment and implementation issues.HF, a leading cause of morbidity and mortality, often involves selenium deficiency, associated with adverse outcomes (1).

While iron supplementation is recommended, selenium´s role in HF is under-researched.

Studies  suggest cardiovascular benefits from selenium, highlighting the need for further investigation.The pilot study will be a multi-center, double-blind, placebo-controlled trial. The intervention group will receive 200 µg of Selenoprecise daily, while the control group will receive a placebo.

Primary outcomes include HF hospitalizations and cardiovascular mortality, with secondary outcomes assessing NT-proBNP levels and quality of life.

Managed by a multidisciplinary team, the study will span five years.The pilot study will provide the necessary groundwork to develop a comprehensive and well-designed study.1. Zhang X.. et al.

Selenium status and cardiovascular diseases: meta-analysis of prospective observational studies and randomized controlled trials. Eur J Clin Nutr 2016; 70: 162-169.